Sovargen

News

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.